Sign In
Buy RDY
$11.85
+0.0200 (+0.169%)
At Close: Jul 31, 2026
GUANGZHOU, China and HYDERABAD, India , March 27, 2025 /PRNewswire/ -- Bio-Thera Solutions (688177:SH; "Bio-Thera"), a commercial-stage biopharmaceutical company developing a pipeline of innovative
FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review
12:16pm, Wednesday, 19'th Mar 2025
Dr. Reddy and Alvotech announce the FDA acceptance of the BLA for their proposed biosimilar candidate of Amgen's Prolia and Xgeva for review.
HYDERABAD, India & REYKJAVIK, Iceland--(BUSINESS WIRE)---- $RDY #AVT03--Alvotech and Dr. Reddy's announce FDA acceptance of Biologic License Application for AVT03, a proposed biosimilar to Prolia® an
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDYS--Dr. Reddy's issues a nationwide recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, due to mislabeling of infusion bag.
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories SA today announced that it has entered into a license agreement with Henlius related to the commercialization of HLX15.
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.
06:35am, Thursday, 06'th Feb 2025
SHANGHAI , Feb. 6, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of
Dr. Reddy's Lab: Near-Term Worries And Underappreciated Potential Could Lead To Huge Returns
06:56am, Thursday, 30'th Jan 2025
Dr. Reddy's Lab is undervalued due to exaggerated concerns about Revlimid revenue decline and the underappreciated potential of new high-growth products like biosimilars and GLP-1 drugs. Despite the a
RDY Q3 Earnings Match Estimates, Generics Revenues Rise Y/Y, Stock Down
12:11pm, Friday, 24'th Jan 2025
Dr. Reddy's stock falls on Q3 fiscal 2025 results, wherein earnings match estimates but revenues beat the same.
Dr. Reddy's Laboratories Limited (RDY) Q3 2025 Earnings Call Transcript
03:58pm, Thursday, 23'rd Jan 2025
Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q3 2025 Earnings Conference Call January 23, 2025 9:00 AM ET Company Participants Richa Periwal – Head-Investor Relations and Analytics Erez Israeli –
Dr. Reddy's Q3 & 9MFY25 Financial Results
12:35pm, Thursday, 23'rd Jan 2025
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #9MFY25--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and nine months ended December 31, 2024.
3 Emerging Market Stocks to Buy as 2024 Wraps Up
12:06pm, Friday, 13'th Dec 2024
Here, we have picked three emerging market stocks, QFIN, YTRA and RDY, which are expected to show robust growth in 2025 on their growth strategies and fundamentals.
Here's Why You Should Add Dr. Reddy's Stock to Your Portfolio
10:50am, Monday, 02'nd Dec 2024
RDY enjoys a strong foothold in the global generics market due to its deep generic drugs pipeline. Its efforts to strengthen its biosimilars portfolio are commendable.
RDY Launches Loqtorzi Biosimilar in India for Nasopharyngeal Carcinoma
11:10am, Friday, 29'th Nov 2024
Dr. Reddy's launches Loqtorzi biosimilar in India under the brand name Zytorvi for treating adults with recurrent or metastatic nasopharyngeal carcinoma.
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. announced the launch of Toripalimab in India.
Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market
08:07am, Tuesday, 26'th Nov 2024
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DrReddys--Dr. Reddy's Laboratories, Inc. and Senores Pharmaceuticals, Inc. today announced the launch of Ivermectin Tablets USP, 3 mg in the U.S. market.
